BACH2 is a tumor suppressor and it is reported to be frequently inactivated in primary pre-B ALL patients via promoter hyper-methylation, missense mutations and deletions, as well as via loss of its upstream regulator paired box 5 (PAX5) [32, 37–39]. Here, PAX5 is linked to neoplasm.